| Original language | English |
|---|---|
| Article number | dks486 |
| Pages (from-to) | 972-974 |
| Number of pages | 3 |
| Journal | Journal of Antimicrobial Chemotherapy |
| Volume | 68 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2013 |
| Externally published | Yes |
Bibliographical note
Funding Information:S. T. has received educational and/or travel grants from Pfizer, VIIV and Janssen Pharmaceuticals. All other authors: none to declare.
Funding Information:
The research leading to these results received funding from the European Community’s Seventh Framework Program (FP7/2007-2013) under the project ‘Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)’—grant agreement no. 223131 and the Agence Natio-nale de Recherche sur le SIDA et les Hépatites virales (ANRS, France).
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- HBV
- HIV antiviral pharmacology
- Hepatic transplantation
- Immunosuppression
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver